Zymeworks Inc. announced the appointment of Scott Platshon as Acting Chief Investment Officer. Platshon will work closely with CEO Kenneth Galbraith to manage cash flows from healthcare assets like Ziihera and pasritamig. He will also oversee the company’s healthcare asset aggregation strategy. Platshon has stepped down from the Board of Directors but will continue as a Partner at EcoR1 Capital, LLC. He expressed eagerness to work with Zymeworks in this new role, highlighting the company’s strong financial foundation and potential for value creation. ZYME stock closed at $23.90 on NASDAQ, up 29.1% on Monday.

Read more at Nasdaq Market News: Zymeworks Appoints Scott Platshon Acting Chief Investment Officer